Loading clinical trials...
Loading clinical trials...
PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study
Conditions
Interventions
Boceprevir (BOC)
PegIntron (PEG)
+1 more
Start Date
September 1, 2005
Primary Completion Date
July 1, 2007
Completion Date
July 1, 2007
Last Updated
October 14, 2015
NCT00199719
NCT06922643
NCT03612973
NCT01866930
NCT05895448
NCT02219490
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions